Table 1.
Characteristics at baseline
| Variables | PRP (n = 20) | Plasma (n = 21) | Placebo (n = 21) |
|---|---|---|---|
| Age in years, mean (SD) | 66.4 ± 5.6 | 66.1 ± 7.5 | 62.5 ± 8.1 |
| Sex, n (%) | |||
| Male | 1 (5%) | 2 (10%) | 2 (10%) |
| Female | 19 (95%) | 19 (90%) | 19 (90%) |
| BMI, mean (SD) | 28.3 ± 4.1 | 28 ± 3.1 | 27.6 ± 3.8 |
| BMI – category, n (%) | |||
| < 25 | 6 (30%) | 4 (19%) | 4 (19%) |
| 25-30 | 5 (25%) | 11 (52%) | 11 (52%) |
| 30-35 | 9 (45%) | 6 (29%) | 6 (29%) |
| Knee, n (%) | |||
| Left | 9 (45%) | 9 (43%) | 11 (52%) |
| Right | 11 (55%) | 12 (57%) | 10 (48%) |
| X-ray, n (%) | |||
| KL2 | 13 (65%) | 13 (62%) | 14 (67%) |
| KL3 | 7 (35%) | 8 (38%) | 7 (33%) |
| Physical Activity, n (%) | 0 (0%) | 0 (0%) | 1 (6%) |
| No | 12 (60%) | 9 (43%) | 9 (43%) |
| Yes | 8 (40%) | 12 (57%) | 12 (57%) |
| Comorbidities, n (%) | |||
| No | 4 (20%) | 5 (24%) | 3 (14%) |
| Yes | 16 (80%) | 16 (76%) | 18 (86%) |
| Duration of symptoms in years, mean (SD) | 8.4 ± 6.5 | 7 ± 8.1 | 7.1 ± 6.9 |
| VAS 0-10 cm for pain, mean (SD) | |||
| Overall | 6.1 ± 1.6 | 5.9 ± 1.4 | 6.6 ± 1.4 |
| At rest | 2.5 ± 2.3 | 1.5 ± 1.9 | 1.9 ± 1.9 |
| At movement | 6.8 ± 2.1 | 6.8 ± 2.1 | 6.8 ± 2 |
| PhGA 0-10 cm, mean (SD) | 4.6 ± 1.9 | 4.6 ± 1.5 | 4.1 ± 1.7 |
| WOMACa, mean (SD) | |||
| Pain 0-20 | 10.7 ± 3.2 | 9.2 ± 2.5 | 11 ± 3.1 |
| Stiffness 0-8 | 4.4 ± 1.7 | 4 ± 1.4 | 4.3 ± 1.8 |
| Function 0-68 | 37.9 ± 11.6 | 33.5 ± 11.2 | 37 ± 12 |
| Total 0-96 | 52.9 ± 15.5 | 46.7 ± 14.3 | 52.3 ± 15.9 |
| KOOS 0-100b, mean (SD) | |||
| Symptoms | 46.1 ± 21 | 56.1 ± 21.6 | 45.4 ± 15.9 |
| Pain | 42.9 ± 15.3 | 50.8 ± 17.5 | 40.7 ± 14.6 |
| ADL | 44.4 ± 15.3 | 51.8 ± 18.6 | 45.4 ± 16.2 |
| Sport/Recreation | 12.8 ± 10.9 | 29.8 ± 21 | 17.4 ± 12.2 |
| QOL | 18.1 ± 13.9 | 29.5 ± 16.4 | 25 ± 15.3 |
| TUGT (s), mean (SD) | 13.6 ± 2.8 | 13.8 ± 3.1 | 13.6 ± 3 |
| US – synovitis, n (%) | |||
| No | 6 (30%) | 2 (10%) | 1 (5%) |
| GS1 | 8 (40%) | 6 (29%) | 2 (10%) |
| GS2 | 4 (20%) | 5 (24%) | 7 (33%) |
| GS3 | 2 (10%) | 8 (38%) | 11 (52%) |
| US - power doppler, n (%) | |||
| No | 16 (80%) | 17 (81%) | 18 (86%) |
| Grade 1 | 1 (5%) | 3 (14%) | 3 (14%) |
| Grade 2 | 3 (15%) | 1 (5%) | 0 (0%) |
| US – effusion, n (%) | |||
| No | 6 (30%) | 2 (10%) | 3 (14%) |
| 0-2mm | 2 (10%) | 3 (14%) | 1 (5%) |
| 2-4mm | 5 (25%) | 6 (29%) | 5 (24%) |
| 4-6mm | 4 (20%) | 3 (14%) | 6 (29%) |
| > 6mm | 3 (15%) | 7 (33%) | 6 (29%) |
| US – cartilagec, n (%) | |||
| 1 | 0 (0%) | 3 (14%) | 1 (5%) |
| 2A | 13 (65%) | 8 (38%) | 13 (62%) |
| 2B | 3 (15%) | 8 (38%) | 4 (19%) |
| 3 | 4 (20%) | 2 (10%) | 3 (14%) |
a higher number associated with worse evaluation
b higher number associated with better evaluation
c For cartilage classification, see the text
Abbreviations: SD standard deviation, BMI body mass index, in kg/m2, KL Kellgren and Lawrence classification for x-ray, VAS visual analogue scale, PhGA physician global assessment, WOMAC Western Ontario and McMaster Universities Index, KOOS Knee Injury and Osteoarthritis Outcome Score, ADL function in daily living, QOL quality of life, TUGT timed up and go test; US: ultrasonography; GS: gray scale